These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Cerebral circulatory insufficiency. Value of a metabolic active drug]. Girard PE; Boucher M Therapeutique; 1973; 49(5):397-400. PubMed ID: 4781833 [No Abstract] [Full Text] [Related]
24. [Therapy of chronic cerebrovascular insufficiency. Controlled comparative study of 2 cerebral antihypoxidosis agents]. Szobor A; Klein M; Bräuer H MMW Munch Med Wochenschr; 1982 Oct; 124(41):897-900. PubMed ID: 6815511 [No Abstract] [Full Text] [Related]
25. [Treatment of chronic cerebrovascular insufficiency: comparison of nimodipine and dihydroergotoxine]. Cosmi F; Caresia L; Panebianco G Clin Ter; 1986 Feb; 116(3):213-20. PubMed ID: 3698528 [No Abstract] [Full Text] [Related]
26. [Therapeutic activity of nicergoline in cerebrovascular syndromes]. Toni E Minerva Med; 1973 Nov; 64(84):4466-73. PubMed ID: 4771472 [No Abstract] [Full Text] [Related]
27. Proxazole in cerebrovascular insufficiency. A controlled clinical trial. Esposito G; De Gregorio M Arzneimittelforschung; 1974 Oct; 24(10):1692-6. PubMed ID: 4611436 [No Abstract] [Full Text] [Related]
28. [Drug therapy of arteriosclerotic circulatory disorders]. Nobbe F Z Allgemeinmed; 1974 Jul; 50(21):957-64. PubMed ID: 4152664 [No Abstract] [Full Text] [Related]
29. [Wallerox increases cerebral circulation and heart capacity]. Heynen U Z Allgemeinmed; 1971 Dec; 47(34):1823-5. PubMed ID: 5003212 [No Abstract] [Full Text] [Related]
30. [A delayed-action therapeutic agent in chronic cerebral circulatory insufficiencies]. Boudouresques J; Papy JJ; Daniel F Therapeutique; 1970 Oct; 46(8):789-92. PubMed ID: 5458910 [No Abstract] [Full Text] [Related]
31. [Therapeutic properties of xanthine nicotinate in the treatment of obliterating arteriopathies]. Tardito E; Azzolini A; De Cristofaro A; Papacharalambus D Minerva Cardioangiol; 1972; 20(7):369-89. PubMed ID: 5050745 [No Abstract] [Full Text] [Related]
32. Trials of 3,7-dimethyl-1-(5-oxohexyl) xanthine (BL 191) in double-blind tests. Buckert D; Harwart D Farmaco Prat; 1976 May; 31(5):264-74. PubMed ID: 773679 [No Abstract] [Full Text] [Related]
33. [Effect of tardokrein in vascular diseases of the nervous system]. Wasilewski R; Rubach K; Bortnowska M Neurol Neurochir Pol; 1972; 6(5):855-60. PubMed ID: 4655989 [No Abstract] [Full Text] [Related]
34. Direct vascular effects of agents used in the pharmacotherapy of cerebrovascular disease on isolated cerebral vessels. Young AR; Bouloy M; Boussard JF; Edvinsson L; MacKenzie ET J Cereb Blood Flow Metab; 1981; 1(1):117-28. PubMed ID: 7328134 [No Abstract] [Full Text] [Related]
35. [Experience with Cosaldon retard in double blind studies]. Dreyer H; Keussen M; Wojtek L Dtsch Med J; 1969 May; 20(10):356-8. PubMed ID: 4919479 [No Abstract] [Full Text] [Related]
36. [Treatment of mental manifestations of chronic cerebral circulatory insufficiency. Clinical and psychometric study]. Lefebvre P; Crocq L; Bernard JG Sem Hop; 1969 Jan; 45(5):312-7. PubMed ID: 4307724 [No Abstract] [Full Text] [Related]
37. [Double-blind study based upon a quatitative appreciation scale of treating chronic cerebrovascular disorders]. Mémin Y; Najean Hueber E Therapeutique; 1973 Nov; 49(9):605-8. PubMed ID: 4600040 [No Abstract] [Full Text] [Related]
38. TREATMENT OF PARKINSONISM IN ELDERLY PATIENTS WITH COSALDON. MUSTARD DM Br J Clin Pract; 1964 Sep; 18():537-8. PubMed ID: 14207669 [No Abstract] [Full Text] [Related]
39. Cerebral vasodilators (second of two parts). Cook P; James I N Engl J Med; 1981 Dec; 305(26):1560-4. PubMed ID: 7031468 [No Abstract] [Full Text] [Related]
40. [Multiple treatment and multimorbidity in the aged. A multiple medication study]. Frankl R; Schmidt-Modrow G ZFA (Stuttgart); 1977 Feb; 53(4):225-9. PubMed ID: 848094 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]